Literature DB >> 18587087

18F-FDG uptake in reactive neck lymph nodes of oral cancer: relationship to lymphoid follicles.

Tassei Nakagawa1, Masatoshi Yamada, Yoshio Suzuki.   

Abstract

UNLABELLED: PET using (18)F-FDG is acceptable as a preoperative diagnostic tool for head and neck cancer. PET combined with CT provides precise localization of neck lymph nodes. Reactive lymphadenopathy is well known as a principal cause of false-positive findings on PET/CT for nodal staging. We investigated the reactive lymph nodes of oral cancer to elucidate the (18)F-FDG-avid area in these nodes.
METHODS: Surgically dissected neck lymph nodes of oral cancer were retrospectively reviewed. Of the patients without pathologic nodal metastasis who underwent preoperative PET/CT, 11 patients with 31 enlarged lymph nodes at 20 levels were enrolled. The maximum standardized uptake value (SUVmax) of each lymph node was recorded. The diameters of the long and short axes were measured by pathologic sectioning, and the sectional surface area was calculated in square millimeters. Besides being stained with hematoxylin and eosin, the sections were immunohistochemically stained by CD79a for B cells, CD3 for T cells, CD68 for macrophages, CD21 for follicular dendritic cells (FDCs), and ubiquitous glucose transporter type 1 (GLUT1). The expression of GLUT1 was compared with staining of lymphoid cells. The numbers of total lymphoid follicles and hyperplastic secondary follicles were counted on CD21 and hematoxylin and eosin sections, respectively. The follicular reactivity index was determined as the ratio of secondary follicles relative to total follicles on the corresponding section. These parameters of reactive lymph nodes were analyzed on a level basis.
RESULTS: GLUT1 was expressed exclusively in lymphoid follicles, whose staining pattern was identical to that of FDCs. The calculated sectional area correlated significantly with the number of total follicles (r = 0.560; P = 0.0101). SUVmax did not correlate with the number of total follicles (P = 0.8947) but correlated significantly with the number of secondary follicles (r = 0.535; P = 0.0152). In addition, a strong positive correlation between SUVmax and the follicular reactivity index was demonstrated (r = 0.829; P < 0.0001).
CONCLUSION: GLUT1 was expressed on cytoplasmic protrusions of FDCs in lymphoid follicles. The (18)F-FDG accumulation in reactive lymphadenopathy depended on secondary follicles. FDCs in germinal centers of secondary follicles are suggested to be avid for (18)F-FDG and the principal cause of false-positive findings for nodal staging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587087     DOI: 10.2967/jnumed.107.049718

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

Review 1.  PET imaging biomarkers in head and neck cancer.

Authors:  Sarah Differding; François-Xavier Hanin; Vincent Grégoire
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-09       Impact factor: 9.236

2.  Imaging findings of primary immunoglobulin G4-related cervical lymphadenopathy.

Authors:  Masaya Kawaguchi; Hiroki Kato; Yusuke Kito; Keisuke Mizuta; Mitsuhiro Aoki; Keizo Kato; Satoshi Goshima; Masayuki Matsuo
Journal:  Neuroradiology       Date:  2017-09-16       Impact factor: 2.804

3.  18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer.

Authors:  Mi Rye Bae; Jong-Lyel Roh; Jae Seung Kim; Jeong Hyun Lee; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-12       Impact factor: 4.553

Review 4.  (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications.

Authors:  Gianpiero Manca; Eleonora Vanzi; Domenico Rubello; Francesco Giammarile; Gaia Grassetto; Ka Kit Wong; Alan C Perkins; Patrick M Colletti; Duccio Volterrani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-19       Impact factor: 9.236

5.  Impact of Lymphoid Follicles and Histiocytes on the False-Positive FDG Uptake of Lymph Nodes in Non-Small Cell Lung Cancer.

Authors:  Seong Young Kwon; Jung-Joon Min; Ho-Chun Song; Chan Choi; Kook-Joo Na; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2011-05-12

6.  Reactive tonsillar enlargement showing strong 18F-FDG uptake during the follow-up of follicular lymphoma.

Authors:  Patricia do Socorro Queiroz Feio; Camilla Borges Ferreira Gomes; Alexandre Simões Nogueira; Luciana Yamamoto Almeida; José Vassallo; Fernando Augusto Soares; Oslei Paes Almeida; Jorge Esquiche León
Journal:  Head Neck Pathol       Date:  2012-09-26

Review 7.  Radiofrequency ablation of lung tumors: imaging features of the postablation zone.

Authors:  Fereidoun G Abtin; Jilbert Eradat; Antonio J Gutierrez; Christopher Lee; Michael C Fishbein; Robert D Suh
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

8.  The value of the SUV ratio between lymph node and bone marrow in predicting pelvic lymphatic metastasis of patients with locally advanced cervical cancer: an integrated PET/CT study.

Authors:  Ying Liu; Jun Hua; Lisheng Liu; Wei Zhang; Shufan Xu; Xiaoliang Chen
Journal:  Nucl Med Commun       Date:  2022-08-25       Impact factor: 1.698

9.  Comparison of dual-energy CT-derived iodine content and iodine overlay of normal, inflammatory and metastatic squamous cell carcinoma cervical lymph nodes.

Authors:  Ahmed M Tawfik; A A Razek; J Matthias Kerl; N E Nour-Eldin; Ralf Bauer; Thomas J Vogl
Journal:  Eur Radiol       Date:  2013-10-02       Impact factor: 5.315

10.  Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer).

Authors:  Young Lan Seo; Dae Young Yoon; Sora Baek; You Jin Ku; Young-Soo Rho; Eun-Jae Chung; Sung Hye Koh
Journal:  Eur Radiol       Date:  2012-05-05       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.